SCHEMBL5702811

SCHEMBL5702811

CCOC(=O)/C=C/CCO[Si](C)(C)C(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.49
ALDH1A1 P00352 1/20 0.44
HCAR2 Q8TDS4 3/20 0.41
TTR P02766 1/20 0.34
DPP4 P27487 1/20 0.34
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
CA14 Q9ULX7 1/20 0.33
ATM Q13315 1/20 0.33
CYP3A4 P08684 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
RAB9A P51151 1/20 0.32
LMNA P02545 2/20 0.31
HTT P42858 1/20 0.31
MLYCD O95822 1/20 0.30
KDM4E B2RXH2 1/20 0.30
FDPS P14324 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5702812 1.00 MAPT (0.49) MAPTALDH1A1HCAR2TTRDPP4
SCHEMBL2631175 0.92 MAPT (0.55) MAPTALDH1A1HCAR2TTRDPP4
SCHEMBL3448747 0.84 HCAR2 (0.39) MAPTHCAR2
SCHEMBL3448750 0.84 HCAR2 (0.39) MAPTHCAR2
SCHEMBL13921360 0.84 HCAR2 (0.39) MAPTHCAR2
SCHEMBL78464 0.84 MAPT (0.44) MAPTALDH1A1HCAR2TTRDPP4
SCHEMBL7698913 0.82 MAPT (0.38) MAPTALDH1A1HCAR2TTRDPP4
SCHEMBL7698911 0.82 MAPT (0.38) MAPTALDH1A1HCAR2TTRDPP4
SCHEMBL4480765 0.80 GABRR1 (0.33) HCAR2NPSR1LMNA
SCHEMBL4483910 0.80 GABRR1 (0.33) HCAR2NPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3766878-B1 NRF2 REGULATORS GLAXOSMITHKLINE IP DEV LTD (GB) 2022-03-16 EP disclosed
CN-108137557-B Nrf2 modulators 葛兰素史密斯克莱知识产权发展有限公司 2021-09-07 CN disclosed
EP-1581480-B1 CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASE-V INHIBITORS PFIZER LTD (GB) 2006-08-23 EP disclosed
US-7045653-B2 cyclopentyl substituted glutaramide derivatives; inhibitors of neutral endopeptidase which may be used to treat cardiovascular disorders, especially hypertension PFIZER, INC. (US) 2006-05-16 US disclosed
EP-1581480-A1 CYCLOPENTIL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASEV INHIBITORS Pfizer Limited (GB) 2005-10-05 EP disclosed
US-20050075392-A1 Novel pharmaceuticals DACK KEVIN NEIL (GB) 2005-04-07 US disclosed
WO-2004056750-A1 CYCLOPENTIL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASE INHIBITORS PFIZER LIMITED (GB) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075392-A1 Novel pharmaceuticals MME, ECE1, ECE2 MAPT 3607/4885ALDH1A1 670/4885HCAR2 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.